GoKawiilFDA weighs 'enforcement discretion' policy allowing sale of unproven peptide drugs
The FDA has submitted an 'Interim Access Policy' on peptide drugs to the White House for review, according to people familiar with the matter cited by the Associated Press. The policy would reportedly let the agency decline to enforce existing restrictions on certain peptides, reassuring compounding pharmacies that they won't face enforcement action if they begin producing them. This comes as FDA scientists are re-reviewing a dozen peptide drugs previously found in 2023 to lack sufficient safety and efficacy data.
GoKawiil's interpretation of the reporting above, not reported fact.
The move suggests the FDA under Secretary Robert F. Kennedy Jr. may be aligning policy with the preferences of the Make America Healthy Again movement, whose members and prominent figures sell and promote peptide products despite unproven claims. Enforcement discretion would not constitute formal approval, but it could effectively open the market to products regulators previously flagged as risky, raising questions about consumer safety oversight. Critics may see this as regulatory science being overridden by political or commercial pressure, though HHS has not commented on the specific proposal.
- FDA has sent an 'Interim Access Policy' on peptides to the White House for review.
- The policy reportedly would let FDA avoid enforcing current restrictions on certain peptide drugs sold by compounding pharmacies.
- In 2023, FDA scientists found a dozen popular peptides lacked safety/efficacy data, and those drugs are now being re-reviewed.
Source: arstechnica.com, 2026-10-16
Published there as: “RFK Jr. proposes FDA look the other way on unproven peptides, report says”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.